PE20221169A1 - Uso de un abridor de canal de potasio kv7 para tratar el dolor - Google Patents

Uso de un abridor de canal de potasio kv7 para tratar el dolor

Info

Publication number
PE20221169A1
PE20221169A1 PE2022001015A PE2022001015A PE20221169A1 PE 20221169 A1 PE20221169 A1 PE 20221169A1 PE 2022001015 A PE2022001015 A PE 2022001015A PE 2022001015 A PE2022001015 A PE 2022001015A PE 20221169 A1 PE20221169 A1 PE 20221169A1
Authority
PE
Peru
Prior art keywords
pain
compound
potassium channel
administration
methods
Prior art date
Application number
PE2022001015A
Other languages
English (en)
Inventor
Jr James Philip Johnson
Gregory N Beatch
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of PE20221169A1 publication Critical patent/PE20221169A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Light Guides In General And Applications Therefor (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)

Abstract

Esta referido a metodos para tratar el dolor, en donde los metodos comprenden administrar oralmente una cantidad efectiva terapeuticamente de N- 4-(6-fluoro-3,4-dihidro-1H-isoquinolin-2-il)-2,6-dimetilfenil -3,3-dimetilbutanamida (Compuesto A), a un sujeto en necesidad de esta. La presente descripcion se dirige ademas a varios metodos mejorados de terapia y administracion del Compuesto A. El dolor tratado por la administracion del Compuesto A es dolor nociceptivo (como dolor radicular, dolor somatico, dolor visceral, dolor de tejido suave, dolor inflamatorio, dolor post operatorio, o una combinacion de estos), dolor neuropatico, o una combinacion de estos.
PE2022001015A 2019-12-06 2020-12-04 Uso de un abridor de canal de potasio kv7 para tratar el dolor PE20221169A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962945093P 2019-12-06 2019-12-06
US201962948010P 2019-12-13 2019-12-13
PCT/US2020/063471 WO2021113757A1 (en) 2019-12-06 2020-12-04 Use of a kv7 potassium channel opener for treating pain

Publications (1)

Publication Number Publication Date
PE20221169A1 true PE20221169A1 (es) 2022-07-25

Family

ID=73856375

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001015A PE20221169A1 (es) 2019-12-06 2020-12-04 Uso de un abridor de canal de potasio kv7 para tratar el dolor

Country Status (14)

Country Link
EP (1) EP4069211A1 (es)
JP (1) JP2023504166A (es)
KR (1) KR20220113411A (es)
CN (1) CN114786658A (es)
AU (1) AU2020397173A1 (es)
BR (1) BR112022010733A2 (es)
CA (1) CA3159436A1 (es)
CL (1) CL2022001477A1 (es)
CR (1) CR20220318A (es)
IL (1) IL293504A (es)
MX (1) MX2022006877A (es)
PE (1) PE20221169A1 (es)
TW (1) TW202133847A (es)
WO (1) WO2021113757A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113698345B (zh) * 2021-10-27 2022-02-01 上海挚盟医药科技有限公司 作为钾通道调节剂的化合物及其制备和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
AU2007288253B2 (en) * 2006-08-23 2013-05-02 Xenon Pharmaceuticals Inc. Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
WO2013067591A1 (en) * 2011-11-10 2013-05-16 Relevare Australia Pty Ltd Topical formulations for pain management
US9248122B2 (en) * 2012-11-28 2016-02-02 Grünenthal GmbH Heteroquinoline-3-carboxamides as KCNQ2/3 modulators
KR20210020892A (ko) * 2018-05-11 2021-02-24 제논 파마슈티칼스 인크. 전압 의존형 칼륨 채널 개방제의 생체 이용률 및 노출을 향상시키는 방법

Also Published As

Publication number Publication date
JP2023504166A (ja) 2023-02-01
AU2020397173A1 (en) 2022-06-23
CN114786658A (zh) 2022-07-22
CR20220318A (es) 2022-10-07
EP4069211A1 (en) 2022-10-12
BR112022010733A2 (pt) 2022-08-23
TW202133847A (zh) 2021-09-16
MX2022006877A (es) 2022-07-11
CA3159436A1 (en) 2021-06-10
KR20220113411A (ko) 2022-08-12
IL293504A (en) 2022-08-01
WO2021113757A1 (en) 2021-06-10
CL2022001477A1 (es) 2023-04-28

Similar Documents

Publication Publication Date Title
MX2020008244A (es) Composiciones y metodos para el tratamiento del cancer y de trastornos inmunitarios usando bacterias de veillonella.
EA202092343A1 (ru) Лечение гнойного гидраденита с использованием ингибиторов jak
CO2018003969A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
MX2020004140A (es) Composiciones y metodos para la eliminacion de celulas cd117+.
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
CO6410292A2 (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
BR112021016833A2 (pt) Compostos com atividade indutora de ferroptose e métodos de seu uso
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
CL2023002549A1 (es) Ciertos compuestos de pladienolida y métodos de uso (divisional).
PE20221169A1 (es) Uso de un abridor de canal de potasio kv7 para tratar el dolor
AR101871A1 (es) Composiciones de glicoconjugado inmunogénico / terapéutico y sus usos
CL2020002605A1 (es) Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cáncer.
CO2019007879A2 (es) Formas cristalinas de tebipenem pivoxil, composiciones que incluyen a las mismas, métodos de fabricación, y métodos de utilización
EA202191170A1 (ru) Комбинированная терапия для лечения гематологических заболеваний
AR106538A1 (es) Métodos y composiciones para el tratamiento de la amiloidosis
AR103118A1 (es) Tratamientos médicos basados en anamorelina
CO2022008001A2 (es) Métodos para el tratamiento de trastornos depresivos
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
AR071779A1 (es) Formulaciones de emulsion narcotica para el tratamiento del dolor quirurgico
CL2023002321A1 (es) Abridor de canales de potasio activado por voltaje para uso en el tratamiento de la anhedonia.
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
EA202190798A1 (ru) Ротамерные изомеры 4-алкил-5-гетероарил-3h-1,2-дитиол-3-тионов
BR112022009794A2 (pt) Método para tratar câncer no pulmão